Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson's disease by enhancing Nrf2 activity

Neuroscience

Volumn 286, Issue , 2015, Pages 131-140

  Jing, X ^a   Shi, H ^a   Zhang, C ^b   Ren, M ^a   Han, M ^a   Wei, X ^a   Zhang, X ^a   Lou, H ^a  

^a SHANDONG UNIVERSITY   (China)

^b Jinan Women and Children Hospital   (China)

Author keywords

6 OHDA; Dimethyl fumarate; Nrf2; Parkinson's disease

Indexed keywords

FUMARIC ACID DIMETHYL ESTER; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2; FUMARIC ACID DERIVATIVE; NEUROPROTECTIVE AGENT; NFE2L2 PROTEIN, HUMAN; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTIOXIDANT RESPONSIVE ELEMENT; C57BL MOUSE; CELL SURVIVAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA PARS COMPACTA; TUMOR CELL LINE;

ANIMALS; ANTIOXIDANT RESPONSE ELEMENTS; CELL LINE, TUMOR; CELL SURVIVAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; FUMARATES; HUMANS; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PARS COMPACTA; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84916620611     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.11.047     Document Type: Article

References (22)

1. Albrecht P., Bouchachia I., Goebels N., Henke N., Hofstetter H.H., Issberner A., Kovacs Z., Lewerenz J., Lisak D., Maher P., Mausberg A.K., Quasthoff K., Zimmermann C., Hartung H.P., Methner A. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation 2012, 9:163.
2. Burton N.C., Kensler T.W., Guilarte T.R. In vivo modulation of the Parkinsonian phenotype by Nrf2. Neurotoxicology 2006, 27:1094-1100.
3. Chao X.J., Chen Z.W., Liu A.M., He X.X., Wang S.G., Wang Y.T., Liu P.Q., Ramassamy C., Mak S.H., Cui W., Kong A.N., Yu Z.L., Han Y.F., Pi R.B. Effect of tacrine-3-caffeic acid, a novel multifunctional anti-Alzheimer's dimer, against oxidative-stress-induced cell death in HT22 hippocampal neurons: involvement of Nrf2/HO-1 pathway. CNS Neurosci Ther 2014, 20:840-850.
4. Chen P.C., Vargas M.R., Pani A.K., Smeyne R.J., Johnson D.A., Kan Y.W., Johnson J.A. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proc Natl Acad Sci U S A 2009, 106:2933-2938.
5. Cuadrado A., Moreno-Murciano P., Pedraza-Chaverri J. The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease. Expert Opin Ther Targets 2009, 13:319-329.
6. Ellrichmann G., Petrasch-Parwez E., Lee D.H., Reick C., Arning L., Saft C., Gold R., Linker R.A. Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS One 2011, 6:e16172.
7. Jakel R.J., Townsend J.A., Kraft A.D., Johnson J.A. Nrf2-mediated protection against 6-hydroxydopamine. Brain Res 2007, 1144:192-201.
8. Jazwa A., Rojo A.I., Innamorato N.G., Hesse M., Fernández-Ruiz J., Cuadrado A. Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid Redox Signal 2011, 14:2347-2360.
9. Jing X., Ren D., Wei X., Shi H., Zhang X., Perez R.G., Lou H., Lou H. Eriodictyol-7-O-glucoside activates Nrf2 and protects against cerebral ischemic injury. Toxicol Appl Pharmacol 2013, 273:672-679.
10. Kaidery N.A., Banerjee R., Yang L., Smirnova N.A., Hushpulian D.M., Liby K.T., Williams C.R., Yamamoto M., Kensler T.W., Ratan R.R., Sporn M.B., Beal M.F., Gazaryan I.G., Thomas B. Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. Antioxid Redox Signal 2013, 18:139-157.
11. Klintworth H., Newhouse K., Li T., Choi W.S., Faigle R., Xia Z. Activation of c-Jun N-terminal protein kinase is a common mechanism underlying paraquat- and rotenone-induced dopaminergic cell apoptosis. Toxicol Sci 2007, 97:149-162.
12. Kumar H., Koppula S., Kim I.S., More S.V., Kim B.W., Choi D.K. Nuclear factor erythroid 2-related factor 2 signaling in Parkinson disease: a promising multi therapeutic target against oxidative stress, neuroinflammation and cell death. CNS Neurol Disord Drug Targets 2012, 11:1015-1029.
13. Lin S.X., Lisi L., Dello Russo C., Polak P.E., Sharp A., Weinberg G., Kalinin S., Feinstein D.L. The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro 2011, 3:e00055.
14. Linker R.A., Lee D.H., Ryan S., van Dam A.M., Conrad R., Bista P., Zeng W., Hronowsky X., Buko A., Chollate S., Ellrichmann G., Brück W., Dawson K., Goelz S., Wiese S., Scannevin R.H., Lukashev M., Gold R. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011, 134:678-692.
15. Petri S., Körner S., Kiaei M. Nrf2/ARE Signaling Pathway: Key Mediator in Oxidative Stress and Potential Therapeutic Target in ALS. Neurol Res Int 2012, 2012:878030.
16. Rojo A.I., Innamorato N.G., Martin-Moreno A.M., De Ceballos M.L., Yamamoto M., Cuadrado A. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 2010, 58:588-598.
17. Scannevin R.H., Chollate S., Jung M.Y., Shackett M., Patel H., Bista P., Zeng W., Ryan S., Yamamoto M., Lukashev M., Rhodes K.J. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the Nrf2 pathway. J Pharmacol Exp Ther 2012, 341:274-284.
18. Tobón-Velasco J.C., Vázquez-Victorio G., Macías-Silva M., Cuevas E., Ali S.F., Maldonado P.D., González-Trujano M.E., Cuadrado A., Pedraza-Chaverrí J., Santamaría A. S-allyl cysteine protects against 6-hydroxydopamine-induced neurotoxicity in the rat striatum: involvement of Nrf2 transcription factor activation and modulation of signaling kinase cascades. Free Radic Biol Med 2012, 53:1024-1040.
19. Tobón-Velasco J.C., Limón-Pacheco J.H., Orozco-Ibarra M., Macías-Silva M., Vázquez-Victorio G., Cuevas E., Ali S.F., Cuadrado A., Pedraza-Chaverrí J., Santamaría A. 6-OHDA-induced apoptosis and mitochondrial dysfunction are mediated by early modulation of intracellular signals and interaction of Nrf2 and NF-κB factors. Toxicology. 2013, 304:109-119.
20. von Otter M., Landgren S., Nilsson S., Celojevic D., Bergström P., Hakansson A., Nissbrandt H., Drozdzik M., Bialecka M., Kurzawski M., Blennow K., Nilsson M., Hammarsten O., Zetterberg H. Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease. BMC Med Genet 2010, 11:36.
21. von Otter M., Landgren S., Nilsson S., Zetterberg M., Celojevic D., Bergström P., Minthon L., Bogdanovic N., Andreasen N., Gustafson D.R., Skoog I., Wallin A., Tasa G., Blennow K., Nilsson M., Hammarsten O., Zetterberg H. Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract. Mech Ageing Dev 2010, 131:105-110.
22. Zhu K.Y., Fu Q., Leung K.W., Wong Z.C., Choi R.C., Tsim K.W. The establishment of a sensitive method in determining different neurotransmitters simultaneously in rat brains by using liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 2011, 879:737-742.